| Alhemo |
761315 |
001 |
351(a) |
concizumab-mtci |
Injection |
Subcutaneous |
60MG/1.5ML (40MG/ML) |
Autoinjector |
2024/12/20
|
Novo Nordisk Inc. |
Rx |
Licensed |
N/A |
N/A |
| Alhemo |
761315 |
002 |
351(a) |
concizumab-mtci |
Injection |
Subcutaneous |
150MG/1.5ML (100MG/ML) |
Autoinjector |
2024/12/20
|
Novo Nordisk Inc. |
Rx |
Licensed |
N/A |
N/A |
| Alhemo |
761315 |
003 |
351(a) |
concizumab-mtci |
Injection |
Subcutaneous |
300MG/3ML (100MG/ML) |
Autoinjector |
2024/12/20
|
Novo Nordisk Inc. |
Rx |
Licensed |
N/A |
N/A |
| Pyzchiva |
761373 |
003 |
351(k) Interchangeable |
ustekinumab-ttwe |
Injection |
Subcutaneous |
45MG/0.5ML |
Single-Dose Vial |
2024/12/20
|
Samsung Bioepis Co., Ltd. |
Rx |
Licensed |
ustekinumab |
Stelara |
| symvess |
125812 |
001 |
351(a) |
acellular tissue engineered vessel-tyod |
Implant |
Implantation |
6 MM IN INNER DIAMETER,~42 CM LENGTH |
Tray & Lid |
2024/12/19
|
Humacyte Global Inc. |
Rx |
Licensed |
|
N/A |
| ryoncil |
125706 |
001 |
351(a) |
remestemcel-L-rknd |
Suspension |
Intravenous |
6.68X10^CELL/ML |
Single-Dose Vial |
2024/12/18
|
Mesoblast, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Steqeyma |
761338 |
001 |
351(k) Interchangeable |
ustekinumab-stba |
Injection |
Subcutaneous |
45MG/0.5ML |
Pre-Filled Syringe |
2024/12/17
|
CELLTRION, Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Steqeyma |
761338 |
002 |
351(k) Interchangeable |
ustekinumab-stba |
Injection |
Subcutaneous |
90MG/ML |
Pre-Filled Syringe |
2024/12/17
|
CELLTRION, Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Steqeyma |
761338 |
003 |
351(k) Interchangeable |
ustekinumab-stba |
Injection |
Intravenous |
130MG/26ML (5MG/ML) |
Single-Dose Vial |
2024/12/17
|
CELLTRION, Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Unloxcyt |
761297 |
001 |
351(a) |
cosibelimab-ipdl |
Injection |
Intravenous |
300MG/5ML (60MG/ML) |
Single-Dose Vial |
2024/12/13
|
Checkpoint Therapeutics, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Bizengri |
761352 |
001 |
351(a) |
zenocutuzumab-zbco |
Injection |
Intravenous |
375MG/18.75ML (20MG/ML) |
Single-Dose Vial |
2024/12/04
|
Merus NV |
Rx |
Licensed |
N/A |
N/A |
| Jivi |
125661 |
005 |
351(a) |
Antihemophilic factor (recombinant), PEGylated-aucl |
For Injection |
Intravenous |
4000IU |
Single-Dose Vial |
2024/12/02
|
Bayer HealthCare LLC |
Rx |
Licensed |
N/A |
N/A |
| Yesintek |
761406 |
001 |
351(k) Interchangeable |
ustekinumab-kfce |
Injection |
Subcutaneous |
45MG/0.5ML |
Single-Dose Vial |
2024/11/29
|
Biocon Biologics Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Yesintek |
761406 |
002 |
351(k) Interchangeable |
ustekinumab-kfce |
Injection |
Subcutaneous |
45MG/0.5ML |
Pre-Filled Syringe |
2024/11/29
|
Biocon Biologics Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Yesintek |
761406 |
003 |
351(k) Interchangeable |
ustekinumab-kfce |
Injection |
Subcutaneous |
90MG/ML |
Pre-Filled Syringe |
2024/11/29
|
Biocon Biologics Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Yesintek |
761406 |
004 |
351(k) Interchangeable |
ustekinumab-kfce |
Injection |
Intravenous |
130MG/26ML (5MG/ML) |
Single-Dose Vial |
2024/11/29
|
Biocon Biologics Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| regenecyte |
125764 |
001 |
351(a) |
HPC, Cord Blood |
Injection |
Intravenous |
>/=1.25x10E6 VIABLE CD34+ CELLS/UNIT IN >/=9x10E8 TNCs/UNIT |
Bag |
2024/11/21
|
StemCyte, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Ziihera |
761416 |
001 |
351(a) |
zanidatamab-hrii |
For Injection |
Intravenous |
300MG |
Single-Dose Vial |
2024/11/20
|
Jazz Pharmaceuticals Ireland Limited |
Rx |
Licensed |
N/A |
N/A |
| KEBILIDI |
125722 |
001 |
351(a) |
eladocagene exuparvovec-tneq |
Suspension |
Intraputaminal |
5.6x10^11VG/ML |
Single-Dose Vial |
2024/11/13
|
PTC Therapeutics |
Rx |
Licensed |
N/A |
N/A |
| Aucatzyl |
125813 |
001 |
351(a) |
Obecabtagene autoleucel |
Suspension |
Intravenous |
410 × 10^6CAR+ T CELLS TOTAL; DELIVERED AS A SPLIT DOSE IN 3-5 BAGS ON DAY 1 & 10 |
Bag |
2024/11/08
|
Autolus, Inc. |
Rx |
Licensed |
N/A |
N/A |